AXSM 最新10-Q变化
将 AXSM 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-11-02 与上一份 10-Q · 2026-08-10
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +1 | −1 | ~33 | 56 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 14 |
| 控制与程序 | 无段落级文字变化 | 0 | 0 | 0 | 14 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 14 |
| 风险因素 | 部分风险因素更新 | +4 | −4 | ~59 | 461 |
| 其他信息 | 无段落级文字变化 | 0 | 0 | 0 | 14 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-11-02
Income tax benefit (expense). We recorded an income tax expense of $0.1 million and $0.2 million for the three and nine months ended September 30, 2026, respectively, due to unfavorable return-to-provision adjustments attributable to certain foreign tax returns filed during the period. We did not re…
相对上期删除的文字 · 来源:10-Q · 2026-08-10
Income tax expense. We recorded an income tax expense of $0.1 million for the three and six months ended June 30, 2026. We recorded an income tax benefit of $1.0 million for the same periods in 2025.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-11-02
If any of our products do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.
Further, executive orders were signed to implement MFN drug pricing policies designed to align certain prescription drug prices in the U.S. to lower prices available in other countries. Since issuance of these executive orders, the U.S. administration has begun implementing MFN pricing through a com…
There are also federal and state laws governing commercial communication and data privacy, including the CAN-SPAM Act, the Telephone Consumer Protection Act (TCPA), and comprehensive state privacy laws such as the CCPA and CPRA. The CAN-SPAM Act, among other things, obligates the sender of commercia…
Further, the ACA expanded the 340B drug discount program to additional facilities for outpatient drugs. These facilities may purchase drugs at the discounted price provided to Medicaid and dispense drugs to people with commercial insurance coverage. This program has greatly expanded over time with q…
相对上期删除的文字 · 来源:10-Q · 2026-08-10
If any of our products do not achieve broad market acceptance, we may be unable to generate substantial product revenues.
Further, executive orders were signed to implement MFN drug pricing policies designed to align certain prescription drug prices in the U.S. to lower prices available in other countries. Since issuance of these executive orders, the U.S. administration has begun implementing MFN pricing through a com…
There are also federal and state laws on marketing and solicitation, such as CAN-SPAM. The CAN-SPAM Act, among other things, obligates the sender of commercial emails to provide recipients with the ability to opt out of receiving future commercial emails from the sender. Any failure by us to comply …
Further, the ACA expanded the 340B drug discount program to additional facilities for outpatient drugs. These facilities may purchase drugs at the discounted price provided to Medicaid and dispense drugs to people with commercial insurance coverage. This program has greatly expanded over time with q…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议